Author of

• 20039

  +

  Poster Display Session (ID 63)

  • Event: ELCC 2017
  • Type: Poster Display Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1

  • 19878

    +

    122P - Response to Metabolically Supported Chemotherapy (MSCT) with weekly carboplatin/paclitaxel in advanced stage/metastatic (Stage IV) non-small cell lung cancer: A survival, efficacy and tolerability analysis (ID 184)

    12:30 - 13:00  |  Author(s): A. Slocum
    • Abstract

    Background:
    Metabolically supported chemotherapy (MSCT), is defined as the application of standard chemotherapy protocols concomitant to the administration of pharmacological doses of regular insulin and the development of hypoglycemia, and following fasting starting the previous day. This study aims to evaluate the efficacy and the tolerability of MSCT combining carboplatin and paclitaxel in the treatment of advanced/metastatic non-small cell lung cancer (NSCLC).
    
    Methods:
    This study is a retrospective single center analysis of all patients diagnosed with metastatic (stage IV) NSCLC that received MSCT combining carboplatin and paclitaxel at our clinic between March 2010 and June 2015.
    
    Results:
    44 patients were included in our study. While 39 (88.6%) of the patients were male, their median age was 65 years (range 35-87). Adenocarcinoma was diagnosed in 34 (77.3%) of the patients. 18 (40.9%) of the patients had brain metastases and ECOG PS was ≥2 in the case of 36 (81.8%) of the patients. When the response evaluation for this study was carried out at the end of 6 cycles of treatment, 42 out of 44 patients included in this analysis remained alive. Statistical analysis revealed a mean overall survival (OS) of 43.4 months, mean progression-free survival (PFS) of 41.8 months and 1-year survival rate of 86.1%.
    
    Conclusions:
    This study demonstrates that a metabolically supported form of applying weekly paclitaxel at a dose of 75 mg/m[2] combined with weekly carboplatin at a dose of AUC 2 may bring about remarkable improvements in the survival rates of patients with advanced and metastatic NSCLC.
    
    Clinical trial identification:
    
    
    Legal entity responsible for the study:
    Kemerburgaz University Bahcelievler Medical Park Hospital and ChemoThermia Oncology Center
    
    Funding:
    N/A
    
    Disclosure:
    All authors have declared no conflicts of interest.